<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Tevogen Bio Holdings Inc — News on 6ix</title>
    <link>https://6ix.com/company/tevogen-bio-holdings-inc</link>
    <description>Latest news and press releases for Tevogen Bio Holdings Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 27 Apr 2026 15:50:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/tevogen-bio-holdings-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ce2778dffbe2df11e551.webp</url>
      <title>Tevogen Bio Holdings Inc</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc</link>
    </image>
    <item>
      <title>Tevogen.AI Nears Completion of PredicTcell™ Training; Initiates Commercial Readiness and Debuts Internal Application Portal</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogenai-nears-completion-of-predictcelltm-training-initiates-commercial-readiness-and-debuts-internal-application-portal</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogenai-nears-completion-of-predictcelltm-training-initiates-commercial-readiness-and-debuts-internal-application-portal</guid>
      <pubDate>Mon, 27 Apr 2026 15:50:00 GMT</pubDate>
      <description>WARREN, N.J., April 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress within its artificial intelligence initiative, Tevogen.AI, including the near completion of its PredicTcell™ training algorithm and early steps toward commercial readiness. PredicTcell™, Tevogen.AI’s proprietary machine learning model designed to identify immunologically active peptides, is approaching the final stages of its training phase. The mo</description>
    </item>
    <item>
      <title>Tevogen Advances Strategic CRO Evaluation to Expand Clinical Research Delivery Capabilities and Drive Revenue Growth</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-advances-strategic-cro-evaluation-to-expand-clinical-research-delivery-capabilities-and-drive-revenue-growth</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-advances-strategic-cro-evaluation-to-expand-clinical-research-delivery-capabilities-and-drive-revenue-growth</guid>
      <pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
      <description>Potential transaction expected to add $20M+ in revenue and support double-digit growth, further strengthening Tevogen’s position in oncology, rare diseases,</description>
    </item>
    <item>
      <title>Tevogen Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-regains-compliance-with-nasdaq-minimum-bid-price-requirement</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-regains-compliance-with-nasdaq-minimum-bid-price-requirement</guid>
      <pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
      <description>WARREN, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) received written notice (the “Notification</description>
    </item>
    <item>
      <title>Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Speak at Microsoft Fabric Community Conference (FabCon 2026)</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-cio-and-head-of-tevogenai-mittul-mehta-to-speak-at-microsoft-fabric-community-conference-fabcon-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-cio-and-head-of-tevogenai-mittul-mehta-to-speak-at-microsoft-fabric-community-conference-fabcon-2026</guid>
      <pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
      <description>WARREN, N.J., March 18, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that Mittul Mehta, Chief</description>
    </item>
    <item>
      <title>Tevogen.AI Reports Advancements in PredicTcell™ Beta, Demonstrates Improved Precision Metrics and Expands Proprietary AI Infrastructure</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogenai-reports-advancements-in-predictcelltm-beta-demonstrates-improved-precision-metrics-and-expands-proprietary-ai-infrastructure</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogenai-reports-advancements-in-predictcelltm-beta-demonstrates-improved-precision-metrics-and-expands-proprietary-ai-infrastructure</guid>
      <pubDate>Fri, 13 Mar 2026 16:30:00 GMT</pubDate>
      <description>Tevogen.AI reports improved PredicTcell™ beta accuracy, expanding its peptide database and AI platform to accelerate drug discovery and future pharma partnerships. Tevogen.AI reports improved PredicTcell™ beta accuracy, expanding its peptide database and AI platform to accelerate drug discovery and future pharma partnerships. WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artifici</description>
    </item>
    <item>
      <title>Tevogen Reaffirms Capital Discipline as Lead Investor Maintains Holdings and Company Limits Share Utilization</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-reaffirms-capital-discipline-as-lead-investor-maintains-holdings-and-company-limits-share-utilization-213</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-reaffirms-capital-discipline-as-lead-investor-maintains-holdings-and-company-limits-share-utilization-213</guid>
      <pubDate>Fri, 13 Mar 2026 04:00:00 GMT</pubDate>
      <description>Lead investor confirmed his intention to maintain his current shareholdings.Company does not anticipate using more than 1% of our authorized shares, including</description>
    </item>
    <item>
      <title>Tevogen CEO Dr. Ryan Saadi Reaffirms Clinical Commitment During International Long COVID Awareness Month; Highlights Synergies of New Leadership Team and Digital Care Platform</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-ceo-dr-ryan-saadi-reaffirms-clinical-commitment-during-international-long-covid-awareness-month-highlights-synergies-of-new-leadership-team-and-digital-care-platform-10</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-ceo-dr-ryan-saadi-reaffirms-clinical-commitment-during-international-long-covid-awareness-month-highlights-synergies-of-new-leadership-team-and-digital-care-platform-10</guid>
      <pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
      <description>WARREN, N.J., March 11, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today issued a statement from Founder and</description>
    </item>
    <item>
      <title>Tevogen Names Leadership Team to Execute Diversified Growth Strategy</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-names-leadership-team-to-execute-diversified-growth-strategy</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-names-leadership-team-to-execute-diversified-growth-strategy</guid>
      <pubDate>Mon, 09 Mar 2026 04:00:00 GMT</pubDate>
      <description>WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the appointment of interim</description>
    </item>
    <item>
      <title>Letter to Shareholders from CEO Dr. Ryan Saadi</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/letter-to-shareholders-from-ceo-dr-ryan-saadi-8</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/letter-to-shareholders-from-ceo-dr-ryan-saadi-8</guid>
      <pubDate>Fri, 06 Mar 2026 05:00:00 GMT</pubDate>
      <description>WARREN, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). Dear Shareholders, As we continue</description>
    </item>
    <item>
      <title>Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-advances-generics-strategy-signs-letter-of-intent-to-evaluate-potential-acquisition-of-apozeal-pharmaceutical-17</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-advances-generics-strategy-signs-letter-of-intent-to-evaluate-potential-acquisition-of-apozeal-pharmaceutical-17</guid>
      <pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
      <description>WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a</description>
    </item>
    <item>
      <title>Tevogen Announces Reverse Stock Split</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-announces-reverse-stock-split-19</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-announces-reverse-stock-split-19</guid>
      <pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
      <description>WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its Board of Directors</description>
    </item>
    <item>
      <title>Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of a Contract Research Organization</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-signs-letter-of-intent-to-evaluate-potential-acquisition-of-a-contract-research-organization</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-signs-letter-of-intent-to-evaluate-potential-acquisition-of-a-contract-research-organization</guid>
      <pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
      <description>WARREN, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a</description>
    </item>
    <item>
      <title>UPDATE - Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/update-tevogen-signs-letter-of-intent-to-evaluate-potential-acquisition-of-sciometrix-and-its-digital-care-management-platform-clinicus</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/update-tevogen-signs-letter-of-intent-to-evaluate-potential-acquisition-of-sciometrix-and-its-digital-care-management-platform-clinicus</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) today announced that it has entered</description>
    </item>
    <item>
      <title>Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of Sciometrix and its Digital Care Management Platform Clinicus</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-signs-letter-of-intent-to-evaluate-potential-acquisition-of-sciometrix-and-its-digital-care-management-platform-clinicus</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-signs-letter-of-intent-to-evaluate-potential-acquisition-of-sciometrix-and-its-digital-care-management-platform-clinicus</guid>
      <pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
      <description>WARREN, N.J. and ROYAL OAK, Mich., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN) today announced that it has entered</description>
    </item>
    <item>
      <title>Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-board-evaluate-potential-one-200000782</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-board-evaluate-potential-one-200000782</guid>
      <pubDate>Fri, 30 Jan 2026 20:00:00 GMT</pubDate>
      <description>Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders Tevogen Board to Evaluate Potential One-Time Special Cash Dividend to Shareholders WARREN, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that its Board of Directors has expressed its intention to evaluate the potential declaration of a one-time special cash dividend to shareholders, contingent upon the achievement of specified financial mi</description>
    </item>
    <item>
      <title>Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-align-long-term-stock-194500201</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-align-long-term-stock-194500201</guid>
      <pubDate>Thu, 29 Jan 2026 19:45:00 GMT</pubDate>
      <description>Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue WARREN, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that the current time- and individual performance-based long-term stock incentive program will be modified to align awards with defined company milestones including reve</description>
    </item>
    <item>
      <title>Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-demonstrates-platform-scalability-multi-140000029</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-demonstrates-platform-scalability-multi-140000029</guid>
      <pubDate>Mon, 12 Jan 2026 14:00:00 GMT</pubDate>
      <description>Jan. 12, 2026, San Francisco. Issued from the J.P. Morgan Healthcare Conference WARREN, N.J., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today reported significant scientific and operational milestones achieved in 2025 within its biotechnology operations, reflecting Tevogen’s continued execution toward a scalable, established, multi-program cell therapy development organization. In 2025, Tevogen advanced its proprietary ExacTcell™ platfor</description>
    </item>
    <item>
      <title>Tevogen CEO Donates Shares to Support Education for Underprivileged Children</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-ceo-donates-shares-support-174000068</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-ceo-donates-shares-support-174000068</guid>
      <pubDate>Mon, 22 Dec 2025 17:40:00 GMT</pubDate>
      <description>WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit organization dedicated to serving underserved communities. “Education is one of the most powerful long-term investments we can make in building healthier, more equitable societies,” said Dr.</description>
    </item>
    <item>
      <title>Tevogen CEO Donates Personal Shares to Support Local Fire Department</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-ceo-donates-personal-shares-161000189</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-ceo-donates-personal-shares-161000189</guid>
      <pubDate>Fri, 19 Dec 2025 16:10:00 GMT</pubDate>
      <description>WARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000 shares of his personal holdings of Tevogen common stock to the Mt. Bethel Fire Company, supporting the organization’s mission to protect the Warren Township community. The donations reflect Dr. Saadi’s continued commitment to supporting first responders and the Warren Township community. “On behalf of the Mt</description>
    </item>
    <item>
      <title>Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock</title>
      <link>https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-ceo-supports-local-law-201500674</link>
      <guid isPermaLink="true">https://6ix.com/company/tevogen-bio-holdings-inc/news/tevogen-ceo-supports-local-law-201500674</guid>
      <pubDate>Thu, 11 Dec 2025 20:15:00 GMT</pubDate>
      <description>WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of his personal shares of common stock to the Warren Township Honorary Policemen’s Benevolent Association (P.B.A.) Local 235. The Warren Township Honorary P.B.A. Local 235 is a non-profit organization dedicated to supporting local schools, community events, and charitable causes. The organization contribute</description>
    </item>
  </channel>
</rss>